MEDIVIR - Simeprevir- Good with and without IFN Combinations!
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1, 2, STELARA, GSK-1605786, Vercirnon, Traficet-EN, Japanese Pharma, Takeda, 4502
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1, 2, STELARA, GSK-1605786, Vercirnon, Traficet-EN, Japanese Pharma, Takeda, 4502
Approval of Simeprevir/IFN/RBV combination (TMC435, once daily Protease Inhibitor, PI, R, HCV, partnered with Tibotec/JNJ) in Japan and progress in IFN free combinations with various drugs has helped Medivir’s (MVIR) stock to reach 52 weeks high after a long wait. With a priority status in US, approval of Simeprevir/IFN/RBV in GT1 pts should happen on or before Nov. 28th 2013 followed by approval in EU in late 13/ early 14. Though Gilead’s Sofosbuvir/IFN/RBV is not far behind, the real competition is for IFN free combinations and MVIR should gain further as the outcome of multiple options in pipeline still remains........ For more detail, please read our report released on October 1, 2013, titled, 'Simeprevir- Good with and without IFN Combinations!'
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1, 2, STELARA, GSK-1605786, Vercirnon, Traficet-EN, Japanese Pharma, Takeda, 4502
Approval of Simeprevir/IFN/RBV combination (TMC435, once daily Protease Inhibitor, PI, R, HCV, partnered with Tibotec/JNJ) in Japan and progress in IFN free combinations with various drugs has helped Medivir’s (MVIR) stock to reach 52 weeks high after a long wait. With a priority status in US, approval of Simeprevir/IFN/RBV in GT1 pts should happen on or before Nov. 28th 2013 followed by approval in EU in late 13/ early 14. Though Gilead’s Sofosbuvir/IFN/RBV is not far behind, the real competition is for IFN free combinations and MVIR should gain further as the outcome of multiple options in pipeline still remains........ For more detail, please read our report released on October 1, 2013, titled, 'Simeprevir- Good with and without IFN Combinations!'
